Celgene’s (CELG) “Buy” Rating Reaffirmed at Leerink Swann

Celgene (NASDAQ:CELG)‘s stock had its “buy” rating reissued by research analysts at Leerink Swann in a research report issued to clients and investors on Wednesday. They currently have a $120.00 price target on the biopharmaceutical company’s stock. Leerink Swann’s price objective would indicate a potential upside of 10.05% from the company’s current price.

A number of other research analysts also recently commented on CELG. BidaskClub raised shares of Celgene from a “sell” rating to a “hold” rating in a research report on Tuesday. Credit Suisse Group set a $128.00 target price on shares of Celgene and gave the company a “buy” rating in a research report on Tuesday. Piper Jaffray Companies reaffirmed a “hold” rating on shares of Celgene in a research report on Sunday. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the company a “hold” rating in a research report on Monday. Finally, Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research report on Wednesday, August 16th. One analyst has rated the stock with a sell rating, twelve have given a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the stock. Celgene currently has an average rating of “Buy” and a consensus target price of $136.21.

Celgene (CELG) traded up $1.04 during midday trading on Wednesday, hitting $109.04. 5,143,500 shares of the company were exchanged, compared to its average volume of 4,782,299. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.65 and a quick ratio of 3.52. The stock has a market cap of $85,850.00, a P/E ratio of 16.88, a price-to-earnings-growth ratio of 0.83 and a beta of 1.77. Celgene has a 1 year low of $94.55 and a 1 year high of $147.17.

Celgene (NASDAQ:CELG) last posted its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion for the quarter, compared to the consensus estimate of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. The company’s revenue was up 10.2% on a year-over-year basis. During the same period last year, the firm posted $1.58 EPS. equities analysts expect that Celgene will post 6.67 earnings per share for the current year.

In other news, insider Terrie Curran sold 1,727 shares of the firm’s stock in a transaction on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now owns 3,925 shares in the company, valued at approximately $564,768.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.95% of the stock is currently owned by company insiders.

Hedge funds have recently added to or reduced their stakes in the company. Thompson Davis & CO. Inc. lifted its stake in shares of Celgene by 5.9% in the second quarter. Thompson Davis & CO. Inc. now owns 773 shares of the biopharmaceutical company’s stock valued at $100,000 after purchasing an additional 43 shares during the period. Arcadia Investment Management Corp MI lifted its stake in shares of Celgene by 118.7% in the third quarter. Arcadia Investment Management Corp MI now owns 737 shares of the biopharmaceutical company’s stock valued at $107,000 after purchasing an additional 400 shares during the period. Robecosam AG acquired a new stake in shares of Celgene in the third quarter valued at about $114,000. Guidant Wealth Advisors acquired a new stake in shares of Celgene in the third quarter valued at about $119,000. Finally, Capital Bank & Trust Co lifted its stake in shares of Celgene by 166.8% in the third quarter. Capital Bank & Trust Co now owns 827 shares of the biopharmaceutical company’s stock valued at $121,000 after purchasing an additional 517 shares during the period. Institutional investors own 80.16% of the company’s stock.

WARNING: “Celgene’s (CELG) “Buy” Rating Reaffirmed at Leerink Swann” was first published by Community Financial News and is the property of of Community Financial News. If you are accessing this report on another website, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.com-unik.info/2017/12/13/celgenes-celg-buy-rating-reaffirmed-at-leerink-swann.html.

Celgene Company Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Analyst Recommendations for Celgene (NASDAQ:CELG)

What are top analysts saying about Celgene? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Celgene and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit